High resolution-mass spectrometry (HR-MS) technology has made several breakthrough improvements in the past 5-7 years, including developments of new HR-MS instruments, data-mining tools and data-acquisition techniques. As a result, HR-MS has become the LC/MS platform of choice for drug metabolite profiling and identification in discovery and development. Among several research groups in the pharmaceutical industry, scientists at Bristol-Myers Squibb implemented mass defect filtering and background subtraction algorithms as well as unique workflows which enabled the effective use of HR-MS in drug biotransformation and disposition studies. Example include reactive metabolite screening, metabolic soft spot analysis, plasma metabolite profiling in humans and metabolite quantification in drug metabolism studies. This webinar will focus on basic concepts and workflows using HR-MS and data-mining algorithms in biotransformation studies. Their effectiveness will also be illustrated using the AB SCIEX TripleTOF™ 5600 System for the study of drug metabolism in BDC rats and CYP inhibition cocktail assays.

Who should attend:

Pharmaceutical & Life Sciences scientists currently using LC/MS/MS based solutions for drug biotransformations and disposition studies within early discovery and who are looking to implement faster, more sensitive, high resolution accurate mass based workflows.